Bicara Therapeutics BCAX 深 沪
已收盘 08-08 16:00:00 美东时间
10.20
0.000
0.00%
华盛通- 最 高10.31
- 今 开10.26
- 成交量 19.41万股
- 最 低 9.9078
- 昨 收 10.20
- 总市值 5.56亿
- 52周最高 28.09
- 市盈率 静 --
- 换手率 0.36%
- 52周最低 7.80
- 委 比 -63.54%
- 总股本 5453.62万
- 历史最高 28.09
- 量 比 0.57
- 振 幅 3.94%
- 历史最低 7.80
- 每 手 1
- 风险率 4.94%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
Bicara Therapeutics Inc. announced that its management will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025. The presentation will be available via webcast on Bicara’s Investor Relations website, with a replay archived post-event. Bicara focuses on developing bifunctional therapies for solid tumors, with its lead program, ficerafusp alfa, targeting EGFR and TGF-β to reverse tumor micro...
06-03 20:01
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025
Bicara Therapeutics presented updated Phase 1/1b trial data on ficerafusp alfa in combination with pembrolizumab for first-line recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). In HPV-negative patients with PD-L1 CPS ≥1, the therapy demonstrated deep and durable responses, including an 80% deep response rate (≥80% tumor shrinkage), median duration of response of 21.7 months, median overall survival (OS) of 21.3 months, and a 46...
06-01 17:12
核心药物试验数据亮眼 大摩维持Bicara Therapeutics(BCAX.US)“买入”评级
摩根士丹利分析师Judah Frommer在Bicara Therapeutics公布Ficerafusp alfa的1/1b期临床试验中期数据后，维持对该股的“买入”评级，目标价保持在36美元。
05-28 14:10
美股大行评级 | 潜在涨幅112.77%！Craig-Hallum上调PLAYSTUDIOS目标价至3美元，评级升至"买入"
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1132955525493317632.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Craig-Hallum：上调PLAYSTUDIOS(MYPS)评级至"买入"，目标价从2美元升至3美元</p> <p>• Leerink Partners：上调Fulcrum Therapeutics(FULC)评级至"
05-24 08:40
Bicara Therapeutics Shares Sink Over 43% On Mixed Phase 1/1b Trial Results: What's Going On?
Bicara Therapeutics Inc. (NASDAQ: BCAX) shares are trading lower Friday following the release of updated interim data.
05-24 04:46
Wells Fargo Upgrades Bicara Therapeutics to Equal-Weight, Maintains Price Target to $8
Wells Fargo analyst Eva Fortea Verdejo upgrades Bicara Therapeutics (NASDAQ:BCAX) from Underweight to Equal-Weight and maintains the price target from $8 to $8.
05-24 02:11
Ross Stores, Deckers Outdoor, Xerox Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were slightly lower this morning, with the Dow futures falli...
05-23 20:38
Market-Moving News for May 23rd
OKLO: 24% | Shares of OKLO and nuclear-linked stocks are trading higher amid report that President Trump to sign orders to boost nuclear power as soon as Friday. BCAX: -36% | Bicara Therapeutics shares are
05-23 19:07
美股大行评级 | 潜在涨幅2840.31%！Mersana Therapeutics获Truist Securities升目标价至10美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130419824951111681.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Truist Securities：维持Mersana Therapeutics(MRSN)"买入"评级，目标价从9美元升至10美元</p> <p>• Guggenheim：维持Cabaletta Bio(CABA)"买入
05-17 08:44
HC Wainwright & Co. Maintains Buy on Bicara Therapeutics, Lowers Price Target to $41
HC Wainwright & Co. analyst Robert Burns maintains Bicara Therapeutics (NASDAQ:BCAX) with a Buy and lowers the price target from $44 to $41.
05-16 19:13
